Inclusion Criteria

Concurrent Medication:

Allowed:

• Pneumocystis prophylaxis.
• Antiretroviral therapy, or other experimental protocols.
• Antipyretics and analgesics as per the treating physician.

Exclusion Criteria

Co-existing Condition:

Patients with the following are excluded:

• Unexplained fever.
• Night sweats.
• Unexplained anemia with hemoglobin < 10 g percent or hematocrit less than 30 percent.
• Hepatic transaminase elevations or total bilirubin values of > 3 times normal.
• Long-term (over 2 weeks) treatment with any drug with known significant anti-Mycobacterium avium complex (MAC) activity including isoniazid, ethambutol, rifampin, raffia, PAS, PZA, amikacin, streptomycin, ethionamide, viomycin, cycloserine, capreomycin, ciprofloxacin, imipenem, rifapentine, gentamicin, or penicillin.

Patients with the following are excluded:

• Known hypersensitivity to clofazimine.
• Mycobacterium avium complex (MAC) infection diagnosis at any site (except isolation from stool in asymptomatic patient).
• Any of the following symptoms at the time of study entry:
• Unexplained fever.
• Night sweats.
• Unexplained anemia with hemoglobin < 10 percent or hematocrit less than 30 percent.
• Hepatic transaminase elevations or total bilirubin values of > 3 times normal.
• Long-term (over 2 weeks) treatment with any drug with known significant anti-MAC activity.

Prior Medication:

Excluded:

• Long-term (over 2 weeks) treatment with any drug with known significant anti-Mycobacterium avium complex (MAC) activity including isoniazid, ethambutol, rifampin, raffia, PAS, PZA, amikacin, streptomycin, ethionamide, viomycin, cycloserine, capreomycin, ciprofloxacin, imipenem, rifapentine, gentamicin, or penicillin.

Group 1:

• AIDS patients with a first episode of Pneumocystis carinii pneumonia (PCP) within 2 to 4 months prior to study entry.
• Group 2:
• Patients with T4 counts < 100 cells/mm3, regardless of prior opportunistic infections or malignancies.
• Karnofsky = or > 70.
• All patients must sign informed consent.